Ocular Therapeutix, Inc. (OCUL)

Market Cap	1.26B
Revenue (ttm)	61.44M
Net Income (ttm)	-174.34M
Shares Out	157.22M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	490,397
Open	8.15
Previous Close	8.05
Day's Range	8.00 - 8.18
52-Week Range	3.76 - 11.78
Beta	1.23
Analysts	Strong Buy
Price Target	16.50 (+105.99%)
Earnings Date	Mar 10, 2025

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL
• Website: https://www.ocutx.com

Financial Performance

In 2023, Ocular Therapeutix's revenue was $58.44 million, an increase of 13.49% compared to the previous year's $51.49 million. Losses were -$80.74 million, 13.7% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 105.99% from the latest price.

Price Target

$16.5

(105.99% upside)

Analyst Consensus: Strong Buy